Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RITSUKO KOMAKI and ARA A VAPORCIYAN.
RITSUKO KOMAKI
Connection Strength
1.096
ARA A VAPORCIYAN
  1. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
    View in: PubMed
    Score: 0.096
  2. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):692-9.
    View in: PubMed
    Score: 0.068
  3. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
    View in: PubMed
    Score: 0.064
  4. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.064
  5. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22.
    View in: PubMed
    Score: 0.060
  6. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
    View in: PubMed
    Score: 0.046
  7. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
    View in: PubMed
    Score: 0.040
  8. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.039
  9. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.039
  10. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.027
  11. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
    View in: PubMed
    Score: 0.024
  12. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9.
    View in: PubMed
    Score: 0.024
  13. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.023
  14. Influence of age on choice of therapy and surgical outcomes in patients with nonsmall cell lung cancer. Am Surg. 2009 Jul; 75(7):598-603; discussion 603-4.
    View in: PubMed
    Score: 0.022
  15. Superior sulcus tumors with vertebral body involvement: a multimodality approach. J Thorac Cardiovasc Surg. 2009 Jun; 137(6):1379-87.
    View in: PubMed
    Score: 0.022
  16. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):412-418.e1-2.
    View in: PubMed
    Score: 0.022
  17. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
    View in: PubMed
    Score: 0.022
  18. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 2008 Dec; 134(6):1349.
    View in: PubMed
    Score: 0.021
  19. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. J Thorac Oncol. 2007 Nov; 2(11):1022-8.
    View in: PubMed
    Score: 0.020
  20. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5.
    View in: PubMed
    Score: 0.019
  21. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):350-7.
    View in: PubMed
    Score: 0.019
  22. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
    View in: PubMed
    Score: 0.018
  23. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 01; 106(3):552-8.
    View in: PubMed
    Score: 0.017
  24. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
    View in: PubMed
    Score: 0.017
  25. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72.
    View in: PubMed
    Score: 0.017
  26. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. J Thorac Cardiovasc Surg. 2005 Dec; 130(6):1601-10.
    View in: PubMed
    Score: 0.017
  27. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55.
    View in: PubMed
    Score: 0.017
  28. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
    View in: PubMed
    Score: 0.017
  29. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7.
    View in: PubMed
    Score: 0.016
  30. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
    View in: PubMed
    Score: 0.016
  31. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
    View in: PubMed
    Score: 0.016
  32. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.016
  33. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
    View in: PubMed
    Score: 0.016
  34. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003 Nov-Dec; 9(6):476-84.
    View in: PubMed
    Score: 0.015
  35. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7.
    View in: PubMed
    Score: 0.015
  36. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
    View in: PubMed
    Score: 0.015
  37. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys. 2003 Mar 01; 55(3):606-16.
    View in: PubMed
    Score: 0.014
  38. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003 Mar 01; 55(3):768-75.
    View in: PubMed
    Score: 0.014
  39. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.014
  40. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.014
  41. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.